Merck Serono S. A.

Giampiero De Luca

Maria Lopez-Bresnahan

Arnaud Ythier

Alain Munafo

Xuliang Jiang

Sean D McKenna

Stephen Arkinstall

Robert K Campbell

Christie Ann Kelton

Rene Lynn Schweickhardt

Chaomei He

Luca Falciola

Meijia Yang

Amaud Ythier

Arnoud Ythier

The present invention is related to the use of Cladribine for the preparation of a pharmaceutical formulation for the treatment of multiple sclerosis, especially relapsing-remitting multiple sclerosis or early secondary progressive multiple sclerosis, wherein the preparation is to be the orally administered and wherein re-treatments are possible.

Cladribine regimen for treating multiple sclerosis

The present invention provides a method of producing functional protein domains, which are fragments of primary translational products consisting of one or more distinct protein domains encoded by specific subsets of exonic sequences. The method is based on the integration, by a single homologous recombination event, of a regulatory unit into the eukaryotic gene coding for the primary translational product at the level of the intronic genomic region immediately adjacent to the exonic sequences which code for the functional protein domain.

Method of producing functional protein domains

This disclosure relates to hybrid antigen binding molecules including at least two polypeptide chains, with at least one polypeptide chain comprises an antigen binding moiety linked to an amino acid sequence of a subunit of a heterodimeric proteinaceous hormone. Also disclosed are methods of making and using such hybrid antigen binding molecules for diagnosis and/or therapy.

Compositions and methods of producing hybrid antigen binding molecules and uses thereof

The present invention is related to the use of Cladribine for the preparation of a pharmaceutical formulation for the treatment of multiple sclerosis, especially relapsing-remitting multiple sclerosis or early secondary progressive multiple sclerosis, wherein the preparation is to be orally administered and wherein re-treatments are possible.

Growing community of inventors

Conches/Geneva, Switzerland

Giampiero De Luca